1Wong EH, Clark R, Leung E, et al. The interaction of RS 25259 -197, a potent and selective antagonist, with 5 - HT3 receptors, in vitro [ J ]. Br J Pharmacol, 1995 Feb, 114(4) :851-9.
2Eglen RM, Lee CH, Smith WL, et al. Pharmacological characterization of RS 25259 - 197, a novel and selec- tive 5 - HT3 receptor antagonist, in vivo [ J ]. Br J Pharmacol, 1995, 114(4) :860-6.
3Grunberg SM, Koeller JM.Palonosetron : a unique 5 - HT3 - receptor antagonist for the prevention of chemotherapy - induced emesis [ J ]. Expert Opin Pharmacother, 2003 Dec,4(12) :2297-303.
4Eisenberg P, MacKintosh FR, Ritch P, et al.Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin -based chemotherapy: a dose - ranging clinical study [ J]. Ann Oncol, 2004 Feb, 15(2) : 330-7.
5Hunt TL, Gallagher SC, Cullen MT JR, et al. Evaluation of safety and pharmacokinetics of consecutive multiple -day dosing of palonosetron in healthy subjects[ J]. J Cliu Phannacol, 2005, 45(5 ) :589-96.
6Stoltz R, Parisi S, Shah A, et al. Pharmacokinetics, metabolism and excretion of intravenous [ 14C ] - palonosetron in healthy human volunteers [ J ]. Biopharm Drug Dispos, 200,25(8) :329-37.
7Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy - in- duced nausea and vomiting following moderately emetogenic chemotherapy : results of a double - blind randomized phase III trial comparing: single doses of palonosetron with ondansetron [ J ]. Ann Oncol, 2003 Oct, 14 (10) : 1570-7.
8Eisenberg P, Figueroa -Vadillo J, Zamora R, et al. Improved prevention of moderately ernetogenic chemo- therapy - induced nausea and vomiting with palonosetron, a pharmacologically novel 5 - HT3 receptor antagonist: results of a phase III, single - dose trial versus dolasetron[ J]. Cancer, 2003, 98 ( 11 ) 2473-82.
9Grote T, Cartmell A, et al. Efficacy of palonosetron (RS-25259) compared with dolasetron in preventing a- cute and delayed moderately emetogenie chemotherapy - induced nausea and vomiting: results of a phase III, randomized, controlled trial [ J ]. Blood, 2002 Part 2, 16 (100) : 497-498.
10Palonosetron improves prevention of chemotherapy- induced nausea and vomiting in elderly patients [ J ]. J Support Oncol, 2005,3(5) :369-74.
2Launchbury AP, Habboubi N. Epruibicin and doxorubicin.. A comparison of their characteristics, therapeutic activity and toxic ity [J]. Cancer Treat Rev, 1993, 19 (3): 197-228.
3Oermanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxici ty [J]. Pediatr Blood Cancer, 2008, 51 (3) : 327-333.
4Pouillart P. Evaluating the role of dexrazoxane as a cardio protectant in cancer patients receiving anthracyclines [J]. Cancer Treat Rev, 2004, 30 (7): 643-650.
5FDA Drug Safety Communication. Abnormal heart rhythms as- sociated with llse of Anzemet (dolasetron mesylate) [EB/OL] . (2011 04 02) [-2011-04-16 ]http: //www. fda. gov/Drugs/ DrugSafety/uern237081. htm.
6Longfield V. Compatibility and stability of 5 HT3 receptor antagonists.- a pharmacology review [J]. Oncol Nurs Fo- rum, 2002, 29 (20): 1469-1482.
7Paz-Ares LG, Smith MR. Genitourinary malignancies [J]. Cancer Chemother Biol Response Modi, 2001, (19) : 573- 595.
8Saito M, Aogi K, Sekine L, et al. Palonosetron plus dexametha- son versus granisetron plus dexamelhasone for prevenlion of nausea and vomiting during chemotherapy : adoullie-blind, dou- hie-dummy, randomised, comparative phase II1 trial [ J ]. Lancel Oneol,2009,10 (2) :115-124.
